Conformationally restrained analogues of pravadoline: nanomolar potent, enantioselective, (aminoalkyl)indole agonists of the cannabinoid receptor
about
Spice drugs are more than harmless herbal blends: a review of the pharmacology and toxicology of synthetic cannabinoidsThe endocannabinoid/endovanilloid N-arachidonoyl dopamine (NADA) and synthetic cannabinoid WIN55,212-2 abate the inflammatory activation of human endothelial cellsCannabinoid CB1-receptor mediated regulation of gastrointestinal motility in mice in a model of intestinal inflammationTerpenes and lipids of the endocannabinoid and transient-receptor-potential-channel biosignaling systemsSynthesis and anti-obesity effects in vivo of Crotadihydrofuran C as a novel PPARγ antagonist from Crotalaria albidaEndocannabinoid binding to the cannabinoid receptors: what is known and what remains unknown.1-Pentyl-3-phenylacetylindoles and JWH-018 share in vivo cannabinoid profiles in miceThe cannabinoid agonist WIN55,212-2 increases intracellular calcium via CB1 receptor coupling to Gq/11 G proteins.The synthesis and pharmacological evaluation of adamantane-derived indoles: cannabimimetic drugs of abuse.Evaluation of (Z)-2-((1-benzyl-1H-indol-3-yl)methylene)-quinuclidin-3-one analogues as novel, high affinity ligands for CB1 and CB2 cannabinoid receptors.Novel approach to the lundurine alkaloids: synthesis of the tetracyclic core.Cannabinoid pharmacology in the cardiovascular system: potential protective mechanisms through lipid signalling.Synthesis and pharmacology of 1-alkyl-3-(1-naphthoyl)indoles: steric and electronic effects of 4- and 8-halogenated naphthoyl substituentsBlockade of β-cell K(ATP) channels by the endocannabinoid, 2-arachidonoylglycerol.The cannabinoid system and its pharmacological manipulation--a review, with emphasis upon the uptake and hydrolysis of anandamide.Spicing things up: synthetic cannabinoids.Sustained antinociceptive effect of cannabinoid receptor agonist WIN 55,212-2 over time in rat model of neuropathic spinal cord injury pain.Targeting CB2 receptors and the endocannabinoid system for the treatment of pain.Latest advances in cannabinoid receptor agonists.Peripherally Selective Cannabinoid 1 Receptor (CB1R) Agonists for the Treatment of Neuropathic PainEffects of the cannabinoid CB1 receptor antagonist rimonabant on distinct measures of impulsive behavior in rats.Visible-light-induced oxidant and metal-free dehydrogenative cascade trifluoromethylation and oxidation of 1,6-enynes with waterEvaluation of first generation synthetic cannabinoids on binding at non-cannabinoid receptors and in a battery of in vivo assays in mice.Cannabinoid receptor agonist WIN 55,212-2 inhibits rat cortical dialysate gamma-aminobutyric acid levels.Bidirectional alterations of hippocampal cannabinoid 1 receptors and their endogenous ligands in a rat model of alcohol withdrawal and dependence.The Endocannabinoid System and Heart Disease: The Role of Cannabinoid Receptor Type 2.Synthesis and Preliminary Biological Evaluation of Indol-3-yl-oxoacetamides as Potent Cannabinoid Receptor Type 2 Ligands.Toxicokinetics of new psychoactive substances: plasma protein binding, metabolic stability, and human phase I metabolism of the synthetic cannabinoid WIN 55,212-2 studied using in vitro tools and LC-HR-MS/MS.
P2860
Q27010555-980E53EB-A4B1-494A-8FA4-862FBC5755AAQ28236199-A52CF7CE-6C40-47CB-8F1D-D5F8353467D2Q28361058-395E9AEF-4302-4F30-AF63-3363C21953A3Q28829964-93C90C9E-106F-4504-A53A-7EBD909DA571Q33594205-81AFB2B3-B0F4-4B2D-BE9B-D1FDDB35E126Q33997873-AE053A86-2D7A-41F3-81B1-6E8C52D875E8Q34236794-2FDBD5FD-CC67-4892-BAD6-26E7BB60777AQ34245210-8F39822B-86E7-4D8D-BF6F-A56B1557DB5CQ34336690-DEC87F89-FF29-4BA7-BD75-3DD5702B80DCQ34610463-C01ED99B-5FA0-4E9F-8F71-36692B3A4EE5Q35250560-E8C79E46-37B3-4A23-B53F-27D814B3BBE5Q35684044-477EEA0B-CCC9-4F66-9F9E-C84101426616Q35818708-9B43A21C-5EAF-4A24-A419-68D06C35AEE1Q36160251-6328CC3B-6CA2-4CC1-B261-9BA17BA627F7Q36655240-CF2FC042-0137-42DA-9C27-E96AE304EDA4Q37237996-0F8043FA-42CE-4DDE-8B3E-71A281A61FECQ37345025-2B1D6540-515F-4AAF-B89B-21183216140EQ37371095-04CB3B35-83D0-4496-8BDD-22D4DB88FF6CQ37638736-1EB6571C-DB5D-41ED-83AE-650D6E8B63B9Q38754299-48A7DA30-ADC7-4C67-979A-6EFF5DD0B3FEQ42076773-1AC61995-FEDB-4B0F-BBCA-C4B3206747C7Q42285443-AA2F3978-E207-4900-8399-DF721927672EQ42581822-81B6C599-B96E-4D46-A843-37F9E7330C5BQ43760360-0BF9560A-ABC9-43A9-8E8D-6312E2368D89Q46077353-83FCDFCE-D86E-4F8A-84E0-5CAA8EB3F28FQ50142905-94CBF88F-88E0-4A80-B33E-D901562855CAQ51216417-623483DC-A6AD-4274-90ED-21DC2FF524C3Q52887320-F207D376-C7BB-4BF8-A71D-193B36AC646D
P2860
Conformationally restrained analogues of pravadoline: nanomolar potent, enantioselective, (aminoalkyl)indole agonists of the cannabinoid receptor
description
1992 nî lūn-bûn
@nan
1992 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1992 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
name
Conformationally restrained an ...... ts of the cannabinoid receptor
@ast
Conformationally restrained an ...... ts of the cannabinoid receptor
@en
Conformationally restrained an ...... ts of the cannabinoid receptor
@nl
type
label
Conformationally restrained an ...... ts of the cannabinoid receptor
@ast
Conformationally restrained an ...... ts of the cannabinoid receptor
@en
Conformationally restrained an ...... ts of the cannabinoid receptor
@nl
prefLabel
Conformationally restrained an ...... ts of the cannabinoid receptor
@ast
Conformationally restrained an ...... ts of the cannabinoid receptor
@en
Conformationally restrained an ...... ts of the cannabinoid receptor
@nl
P2093
P921
P356
P1476
Conformationally restrained an ...... ts of the cannabinoid receptor
@en
P2093
D A Haycock
E R Baizman
F M Casiano
M A Eissenstat
N C Beglin
T E D'Ambra
P304
P356
10.1021/JM00079A016
P407
P577
1992-01-01T00:00:00Z